Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

7.460 -0.180 (-2.36%)
Streaming Delayed Price Updated: 9:45 AM EDT, Jul 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
40 41 Next >
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Adelia Announce Achievement of Milestone
Via Investor Brand Network
Cybin's Psilocybin Analog CYB003 Gets FDA Clearance For Trial To Potentially Treat Major Depressive Disorder
Psychedelic biopharma company Cybin Inc. (NEO: CYBN) has received FDA Investigational New Drug Application (IND) approval for a Phase 1/2a clinical trial evaluating its proprietary CYB003 for treating... 
Via Benzinga
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Allied, Revive Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 3.12% at $0.82 
Via Benzinga
Rebalanced Psychedelic Compounds-Based Drug Stocks Index Down 52.7% YTD
The Psychedelic Compounds-Based Drug Stocks Index is down 52.7% YTD and down 75.9% from its highest point in 2021. 
Via Talk Markets
Why More Attention Needs to Be Paid to Paternal Mental Health
Via Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Initial Results from Feasibility Study
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Moving Forward with Phase 1/2a Clinical Trial after Receiving Key FDA Approval
Via Investor Brand Network
Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Allied, Revive Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: Allied (OTC:ALID) shares closed up 29.44% at $0.56 
Via Benzinga
New Netflix Series to Explore the Use of Psychedelics for Mental Health
Via Investor Brand Network
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 6.63% at $0.71 
Via Benzinga
Psychedelic Stock Gainers And Losers From June 22, 2022
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 4.17% at $3.50 
Via Benzinga
Cybin Closes Fiscal Year 2022, Reports Financial Results And Major Achievements
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), a biopharma company focused on progressing “psychedelics to therapeutics” through proprietary drug discovery platforms announced its financial and business... 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Business Highlights, FY 2022 Results
Via Investor Brand Network
10 Psychedelics CEOs To Pay Attention To In 2022
By Javier Hasse and Aaron Bry. 2020 and 2021 were defining years for the burgeoning psychedelics industry. In 2021 alone, more than $730 million were invested into various psychedelic companies, both... 
Via Benzinga
Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Revive Therapeutics, Numinus Wellness Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 7.43% at $0.31 
Via Benzinga
Advances in Precision Medicine Boost Research on Psychedelics
Via Investor Brand Network
Psychedelic Stock Gainers And Losers From June 17, 2022
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 5.69% at $0.67 
Via Benzinga
Psychedelic Stock Gainers And Losers From June 16, 2022
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 3.08% at $10.05 LOSERS: 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at H.C. Wainwright 1st Annual Mental Health Conference
Via Investor Brand Network
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at H.C. Wainwright 1st Annual Mental Health Conference
Via Investor Brand Network
Cybin to Present at the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022
From Cybin Inc.
Via Business Wire
Psychedelic Stock Gainers And Losers From June 15, 2022
GAINERS: Cybin (AMEX:CYBN) shares closed up 9.11% at $0.62 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Collaborating to Progress Mission to Create Safe, Effective Therapeutics
Via Investor Brand Network
What You Should Know About Ego Death
Via Investor Brand Network
Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider. 
Via Benzinga
World’s Richest Man Says Psychedelics Could Make a Real Difference in Mental Health
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – June 15, 2022 – Elon Musk believes that psychedelics and other plant-based drugs are better than pharma meds in treating a... 
Via FinancialNewsMedia
Psychedelic Stock Gainers And Losers From June 14, 2022
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 9.90% at $9.44 
Via Benzinga
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.